Previous close | 81.76 |
Open | 82.18 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's range | 81.67 - 82.28 |
52-week range | 68.84 - 91.00 |
Volume | |
Avg. volume | 6,307,819 |
Market cap | 108.748B |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | 26.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.76 (3.37%) |
Ex-dividend date | 21 Mar 2024 |
1y target est | N/A |
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.
Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.